Novartis AG announces a strategic review of its 70.68% shareholding in Indian subsidiary, Novartis India Limited.
Swiss pharmaceutical company Novartis AG has announced a strategic review of its Indian subsidiary, Novartis India Limited. The review will include an assessment of the company's 70.68% shareholding in Novartis India. However, the review will not affect Novartis Healthcare Private Limited, which includes the Novartis Corporate Center in Hyderabad and R&D teams conducting clinical trials at over 300 locations in the country. There is no guarantee that the strategic review will be completed in 2024 or result in any transaction.
February 16, 2024
9 Articles